Long follow-up in a rare disorder
Each participant received 563–612 days of open-label treatment, directly extending the short-duration evidence available for AAE-C1INH prophylaxis.
↳ Abstract, Results; Results, Patient characteristics, p. 1652
Abstract
BACKGROUND: Angioedema due to acquired C1-inhibitor deficiency (AAE-C1INH) is a rare disorder characterized by recurrent episodes of angioedema due to excessive bradykinin release. Deucrictibant, an oral B2 receptor antagonist, is currently under development for long-term prophylactic and on-demand treatment in hereditary angioedema. In a recent small double-blind, placebo-controlled crossover trial (EudraCT no. 2021-000720-36), all 3 participants with AAE-C1INH had complete control of angioedema during 8 weeks of treatment with deucrictibant immediate-release capsule. OBJECTIVE: We investigated the long-term efficacy and safety of deucrictibant extended-release tablet as prophylactic treatment in patients with AAE-C1INH. METHODS: In this open-label, single-arm study, patients with AAE-C1INH received deucrictibant 40 mg extended-release tablet once daily. The primary end point was the time-normalized number of investigator-confirmed angioedema attacks per 28 days of exposure to deucrictibant compared to baseline. RESULTS: Four patients with AAE-C1INH were enrolled, 3 of whom were rolled over from the randomized controlled trial of immediate-release deucrictibant. The on-treatment follow-up duration in this study ranged from 563 to 612 days. The mean monthly attack rates at baseline were 1.2, 1.2, 0.9, and 2.1, respectively (mean, 1.35). One mild abdominal attack was reported by one patient 2 days after initiation of deucrictibant treatment; the remaining patients were attack-free during the treatment period. The mean monthly angioedema attack rate for all patients was 0.01. No treatment-related adverse events were reported. CONCLUSION: Deucrictibant extended-release tablet effectively prevented angioedema attacks in patients with AAE-C1INH, with no safety concerns.
Key Claims
Primary findingTentative
Deucrictibant extended-release tablet effectively prevented angioedema attacks in patients with AAE-C1INH, with no safety concerns.
causal efficacy and broad safety framing exceed an uncontrolled four-patient study
Abstract, Conclusion; Clinical implication
SecondaryTentative
The mean monthly angioedema attack rate for all patients was 0.01.
descriptive result from four uncontrolled participants with differing baseline windows
Abstract, Results; Results, Efficacy, p. 1653
SecondarySupported
AECT scores increased to the maximum score of 16 for all patients at the end of the trial, indicating complete disease control.
reported endpoint scores support the observed within-cohort result despite the uncontrolled design
Results, Efficacy, p. 1653
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Detailed longitudinal outcome documentation
The study used daily attack diaries, investigator confirmation, eight scheduled visits, AECT, AE-QoL, TSQM-II, safety testing, and pharmacokinetic sampling.
↳ Methods, Study procedures and objectives, pp. 1651–1652; Figures 2–3
Transparent clinical and safety reporting
Table I reports individual baseline characteristics and concurrent disorders, while Table II accounts for 28 adverse events and their severity. Patient 4's lymphoma diagnosis and treatment are described rather than omitted.
↳ Table I; Results, Patient characteristics, p. 1652; Table II
Limitations
Causal conclusion exceeds the design
The Abstract, Discussion, Conclusion, and Clinical implication say deucrictibant effectively prevented attacks, although the study was open-label, single-arm, and limited to four participants.
↳ Abstract, Conclusion; Discussion, pp. 1654–1655; Clinical implication
Alternative explanations remain incompletely addressed
The analysis does not systematically trace regression to the mean or natural attack variability, and patient 4 received lymphoma-directed therapy during follow-up.
↳ Results, Patient characteristics and Efficacy, pp. 1652–1653
Generalizability claim contradicts stated limitation
The Discussion acknowledges that rarity constrained the sample, then argues that uniform responses among four participants support generalizability.
↳ Discussion, pp. 1654–1655
Nabu Commentary
The study's main value is its long follow-up and detailed patient-level reporting in a disorder with a sparse evidence base. Daily diaries, repeated validated outcome measures, pharmacokinetic sampling, and Table II's adverse-event accounting support the descriptive observations. The principal score constraint is the use of definitive efficacy language for an open-label, single-arm cohort of four participants, three of whom came from the prior trial. The Discussion further weakens contextual calibration by presenting uniform responses as evidence of generalizability immediately after acknowledging the rarity-constrained sample.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Limited2.8
Confidence highContribution
3.3
The study adds 563–612 days of extended-release exposure and outcome reporting in a very rare condition with limited prophylactic evidence. The advance is incremental because three participants rolled over from the earlier deucrictibant trial and only one participant was newly enrolled.
Abstract, Results; Results, Patient characteristics, pp. 1652–1653
“Three participants (patients 1, 2, and 3) rolled over from the randomized placebo-controlled trial.”
Methodological Rigour
2.4
Daily diaries, investigator confirmation, scheduled assessments, validated questionnaires, and detailed adverse-event reporting support longitudinal reconstruction. The causal efficacy conclusion is not identified by the single-arm design, while regression to the mean and concurrent lymphoma treatment remain incompletely addressed.
Methods, Study procedures and objectives, pp. 1651–1652; Results, pp. 1652–1654; Conclusion, p. 1655
“In this open-label, single-arm study”
Reporting
3.3
The manuscript follows a clear progression from eligibility and procedures to patient-level attack, questionnaire, safety, and pharmacokinetic results. Its headline wording presents efficacy and absence of safety concerns more definitively than four uncontrolled observations warrant.
Abstract, Conclusion; Clinical implication, p. 1655
“effectively prevented angioedema attacks in patients with AAE-C1INH, with no safety concerns”
Positioning
2.8
The paper relates the findings to the prior crossover trial, limited AAE-C1INH prophylaxis literature, and a hereditary-angioedema phase 2 study. Its claim that uniform responses support generalizability contradicts the sample-size limitation acknowledged in the same Discussion paragraph.
Introduction, pp. 1650–1651; Discussion, pp. 1654–1655
“the uniformity of treatment responses among all participants supports the reliability and generalizability of the findings”
Lower confidence on Contribution — domain match limited.
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The principal counts, baseline rates, follow-up, and adverse-event totals are generally consistent, but the causal headline framing exceeds what the uncontrolled design establishes. The patient 4 rate of 0.07 attacks per four weeks is also not readily reconciled with one attack over the stated 612-day follow-up.
Research ConductNoted
Ethics approval, consent, registration, funding, study-drug provision, and financial conflicts are disclosed. The sponsor-funded, sponsor-supplied, open-label design creates an expectation-bias risk but no undisclosed or improper conduct is identified.
Flags: 3 declared / 5 total
Reference IntegrityClean
12 of 13 checkable references verified
14 references in manuscript 1 are books, websites or datasets — counted, but not index-checkable
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Sep 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
Long exposure and direct clinical administration place the work beyond a purely conceptual study. For AAE-C1INH specifically, the uncontrolled four-patient evidence remains too preliminary to support routine prescribing or deployment.
Abstract, Methods and Results; Discussion, pp. 1654–1655
“Further prospective studies in patients with AAE-C1INH are needed to confirm the findings”
AI-generated, human-governed. Something look off? Contact us to request a review.